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Cyclooxygenase-2 (COX-2), an inducible form of the enzyme that catalyzes the first step in the synthesis of
prostanoids, is associated with carcinogenesis, which is suspected to promote angiogenesis and tissue invasion of
tumors and resistance to apoptosis. COX-2 is also involved in metastasis and poor prognosis of cancer.
Osteosarcoma with COX-2 positivity is from 67 to 92 %. COX-2-positive rate in metastatic lesions was greater than
that of biopsy and/or resected samples of the primary site in osteosarcoma. And, what role does COX-2 play in
osteosarcoma metastasis? Genetic studies support a cause-effect connection between COX-2 and tumorigenesis.
COX-2 expression had a poor prognosis with regard to metastasis, and patients with increased COX-2 expression in
lung metastases died of the disease. COX-2 expression has also been established as a marker in human
osteosarcoma, and COX-2 inhibition has been suggested as a possible way of improving therapeutic outcome. In
addition, COX-inhibitors inhibit the tumor initiation, matrix metalloproteinases (MMPs), cell differentiation and T cell
proliferation and suppression of the antitumor activity of natural killer cells and macrophages, angiogenic
mechanism. Therefore, we can exert the COX-inhibitors to potentialize the effects of chemotherapeutic agents, and
reverse the metastasis in osteosarcoma to facilitate the patient who may benefit from addition of COX-inhibitors to
standard cytotoxic therapy.
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Cyclooxygeanse-2 (COX-2) is overexpressed in most
solid tumors, such as colorectal, liver, pancreatic, breast,
lung cancer as well as osteosarcoma [1–6]. The activity
of COX-2 is suspected to promote angiogenesis, tissue
invasion of tumors [7], metastasis [8, 9], and resistance
to apoptosis [10, 11]. Genetic studies support a cause-
effect connection between COX-2 and tumorigenesis.
Therefore, we can exert the drugs to affect COX-2 and
achieve the therapies of human malignancies. Both non-
selective non-steroidal anti-inflammatory drugs
(NSAIDs), and selective COX-2 inhibitors can inhibit
proliferation, invasiveness of tumors.
Osteosarcoma is the most common primary bone
tumor generally affecting children and young adults
which has been reported to express COX-2 constitu-
tively. Approximately 20 % of patients present with lung* Correspondence: liubing21st@163.com
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patients metastases occur at a later stage. As we know,
osteosarcoma with COX-2 positivity is from 67 to 92 %
[9, 12, 13]. Dickens et al. [12] reported the COX-2-
positive rate in metastatic lesions was greater than that
of biopsy and/or resected samples of the primary site in
osteosarcoma. And, what role does COX-2 play in osteo-
sarcoma metastasis?Cyclooxygenase
The cyclooxygenases (COX) are enzymes, known as
prostaglandin (PG) rate-limiting synthase, catalyze the
metabolism of arachidonic acid (AA) to PGs. Finally, a
series of biologically active prostaglandins (PGD2, PGE2,
PGF2α, and PGI2) and thromboxane A2 (TXA2) are
formed. There are three isoforms of the enzyme that
have been identified: COX-1, COX-2, and COX-3 [14].
COX-1 is considered a “housekeeping enzyme”, constitu-
tively expressed in human cells. COX-3, an alternate
splice variant of COX-1, is most abundant in the canine
cerebral cortex. COX-2 is an inducible enzyme and isticle distributed under the terms of the Creative Commons Attribution License
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esis, which is suspected to promote angiogenesis and tis-
sue invasion of tumors [7, 15].Molecular factors in metastatic osteosarcoma
The metastatic cancer cells subsequently complete the fol-
lowing steps: Invasion through the extracellular host
matrix and entrance into the circulation (I), survival in the
circulation (II) and evasion of the host immune system
(III), arrest and extravasation at a target organ site (IV), ad-
herence and survival in the target organ microenvironment
(V, VI) and finally formation of neovasculature to allow
growth at the target organ site (VII) [16–21]. PosthumaDe-
Boer J [16] reported that there are many molecular alter-
ations as target for therapy in metastatic osteosarcoma: (I)
Migration and invasion MMPs, m-Calpain, Wnt, Src,
Notch; (II) a Anoikis resistance PI3K/Akt, Src/PI3k/Akt,
Src/Ras/MAPK, NF-κB, Wnt/β-catenin, BcL family, (II) b
Apoptosis resistance Src, NF-κB, Wnt/β-catenin, Fas/FasL;
(III) Evasion of immune system HLA-1, IL-10, Fas; (IV)
Arrest and extravasationCXCR4-CXCL12,CXCR3-CXCL9-
11, CXCR4/MMPs, CXCR3-4/Erk/NF-κB; (V) Adher-
ence Ezrin/MAPK/Akt, Ezrin/β4-Integrin/PI3K, CD44/
Akt/mTOR, (VI) Dormancy Integrin-α5β1, Integrin-
α5β1/Erk/p38, Bcl-XL, IGF/PI3K, ECM; (VII) Angio-
genesis and proliferationEGFR. PDGFR, VEGF, IGFR,
TGF-β, MMPs, VEGF/Erk/NF-κB, VEGF/PI3K, EGFR/
Src/Ras/MAPK/STAT3, Src, Integrin/PI3K/Erk1-2, Wnt/
β-catenin/CyclinD-Survivin.COX-2 promotes metastasis in osteosarcoma
COX-2 overexpression in osteosarcoma increases cell
mobility and invasiveness, which correlates with the oc-
currence of distant metastasis in patients with osteosar-
coma and also may affect post-metastatic survival [8].
The cancer stem cells (CSCs) share several characteris-
tics with embryonic and somatic stem cells including
self-renewal and differentiation abilities, and represent a
small fraction of the cellular population of the tumor.
Osteosarcoma CSCs have been identified in humans and
dogs suggesting that these cells may be responsible for
treatment failure in this disease [22, 23]. Pang LY [24]
reported that global transcriptional analysis and com-
parison with parental cells identified COX-2 expression
to be significantly increased in this population. They
identified that COX-2 was expressed 141-fold more in
CSC spheres than daughter adherent cells. Meanwhile,
COX-2 expression is elevated in cancer stem cells, which
is required for tumoursphere formation, and tumour-
spheres increased invasiveness and tumourigenicity.
They found that COX-2 inhibition had no effect on CSC
growth, or resistance to chemotherapy. However inhib-
ition of COX-2 in daughter cells prevented sphereformation, indicating a potential significant role for
COX-2 in tumor initiation.
Invasion is mediated mainly by matrix metalloprotein-
ases (MMPs). Among them, MMP-2 (gelatinase A) and
MMP-9 (gelatinase B) are known to be strongly corre-
lated with metastatic potential of cancer cells [25]. Lee
EJ [26] reported that COX-2 overexpression enhanced
mobility and invasiveness of U2OS cells, which was ac-
companied by increases of matrix metalloproteinase-2
and -9 (MMP-2 and -9) activities. Selective COX-2 in-
hibitors, NS-398 and celecoxib, inhibited cell prolifera-
tion and abrogated the enhanced mobility, invasiveness
and MMP activities induced by COX-2 overexpression.
In our study, we reported that Celecoxib, a
cyclooxygenase-2 inhibitor, induces apoptosis in human
osteosarcoma cell line MG-63 via down-regulation of
PI3K/Akt [27]. PI3K/Akt plays an essential role in the
cell/extracellar matrix (ECM) and cell/cell adhesion.
Lack of the correct adhesion, the adhesion-dependent
signals will be interrupted, which will result in adhesion-
related apoptosis: anoikis [28]. Activation of PI3K/Akt
signaling has been shown to mediate survival signals
triggered by the engagement of E-cadherin [29] and
other classical cadherins [30, 31]. One possible connec-
tion between integrins and β-catenin is the integrin-
activated, antiapoptotic kinase PKB/Akt. PKB is known
to inhibit the activity of glycogen synthase kinase 3-β, a
serine kinase that functions directly to reduce β-catenin
protein and signaling [32, 33]. It has been established
that brain-derived neurotrophic factor (BDNF) binding
to TrkB receptors results in a highly specific receptor
autophosphorylation [34] and in turn activates the PI3K/
Akt pathway [35]. Another target of the PI3K/Akt path-
way may be survivin [36]. Survivin is a member of the
inhibitor of apoptosis protein (IAP) family, the regula-
tion of survivin by adhesion was examined.
PGE2, downstream of COX-2, can regulate immune
function through inhibition of dendritic cell differentiation
and T cell proliferation and suppression of the antitumor
activity of natural killer cells and macrophages [37].
COX-2 inhibitors blocked tumor growth via an
antiangiogenic mechanism [38]. VEGF plays a key
role in angiogenesis since it stimulates almost every
step in the angiogenic process [39, 40]. Other factors
can stimulate angiogenesis include EGF, bFGF, hep-
atocyte growth factor, interleukin-8, and placental
growth factor [41, 42]. Immunohistochemical analysis
for VEGF revealed that COX-2 inhibitor prominently
suppressed the expression of VEGF in lung meta-
static lesion compared with control treatment. In
addition, it also reduced VEGF, EGF and bFGF
mRNA and protein expression [43]. In vivo, high
doses of meloxicam suppressed LM-8 tumor growth
and lung metastasis [6].
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In this review, we have tried to encompass the role of
COX-2 in the regulation metastasis in osteosarcoma.
COX-2 expression and the abundance of its enzymatic
product PGE2 play key roles in the development of can-
cer. Genetic studies support a cause-effect connection
between COX-2 and tumorigenesis. COX-2 expression
had a poor prognosis with regard to metastasis, and pa-
tients with increased COX-2 expression in lung metasta-
ses died of the disease. COX-2 expression has also been
established as a marker in human osteosarcoma, and
COX-2 inhibition has been suggested as a possible way
of improving therapeutic outcome [8]. Therefore, COX-
2 inhibitors may prove to have a therapeutic role in
counteracting the metastasis of osteosarcoma.
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